To the best of our knowledge, this is the first study to demonstrate that combining quantitative measurement of PR IHC staining with tumor grade and pretreatment serum CA125 level can be used to predict the risk of LNM in patients with endometrioid endometrial cancer. This evidence concerns the gene MUC16 and neoplasm.